ArticleMayo Clinic proceedings. Innovations, quality & outcomes2026
Retrospective Analysis of Long-term Impact of COVID-19 Pandemic on Mammographic Breast Cancer Screening.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine whether the initial decrease in mammographic breast cancer screening (MBCS) rates with the corona virus disease of 2019 (COVID-19) pandemic persisted in the postpandemic times and quantify the impact of health care disparities. Patients and Methods: This retrospective study analyzed data from March 1, 2017 to March 31, 2023 to assess annual MBCS among eligible women (40-75 years) in the Mayo Clinic system. The study period was divided into 4 phases: pre-COVID-19 (2017-2020), early pandemic (2020-2021), mid-pandemic (2021-2022), and late pandemic (2022-2023). Mixed-effects poisson regression estimated incidence rate ratios (IRR), and difference-in-differences assessed temporal trends. Results: The cohort included 239,804 women with a median age of 57 years, of whom 34.9% resided in rural counties. By race, 92% were White, 3.1% Black, 0.4% American Indians, 0.1% Native Hawaiians, 3% Asian, and 1.3% others. Compared with the pre-COVID-19 period, there was a significant decrease in MBCS rate in the early pandemic (IRR=0.891, Conclusion: The COVID-19 pandemic was associated with sustained declines in MBCS through early 2023, disproportionately affecting vulnerable populations but did not widen pre-existing disparities, highlighting the benefits of targeted interventions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.